Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.

被引：0
|
作者：
Hurtado, Alicia
Garcia-Donas, Jesus
Garrigos, Laia
Lainez, Nuria
Redondo, Andres
Fernando Cueva, Juan
Santaballa, Ana
Jesus Rubio, Maria
Palaclo, Isabel
Bover, Isabel
Antonio Lopez-Guerrero, Jose
Prieto, Mario
Garcia-Casado, Zaida
Hernando Polo, Susana
Romero, Nuria
Grande, Enrique
机构：
[1] Hosp Univ Fdn Alcorcon, Alcorcon, Spain
[2] Ctr Integral Oncol Clara Campal, Madrid, Spain
[3] Hosp del Mar, Barcelona, Spain
[4] Complejo Hosp Navarra, Pamplona, Spain
[5] Hosp Univ La Paz, Madrid, Spain
[6] Complexo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain
[7] Hosp Univ La Fe, Valencia, Spain
[8] Politecn La Fe, Valencia, Spain
[9] Hosp Reina Sofia Cordoba, Cordoba, Spain
[10] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain
[11] GEICO, Mallorca, Spain
[12] Son Llatzer Univ Hosp, Mallorca, Spain
[13] Inst Valenciano Oncol, Mol Biol Lab, Valencia, Spain
[14] Ctr Integral Oncol Clara Campal, Madrid, Spain
[15] Fdn Inst Valenciano Oncol, Valencia, Spain
[16] Hosp Univ Ramon Y Cajal, Dept Med Oncol, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps5626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5626
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.
    Garrigos, Laia
    Santaballa, Ana
    Hurtado, Alicia
    Rodriguez-Moreno, Juan Francisco
    Sanchez-escribano, Ricardo
    Redondo, Andres
    Lainez, Nuria
    Rubio, M. Jesus
    Bover, Isabel
    Cueva, Juan Fernando
    Polo, Susana Hernando
    Manuel, Marta Izquierdo
    Prieto, Mario
    Lopez-Guerrero, Jose Antonio
    Garcia-Casado, Zaida
    Perez, Ignacio
    De Las Penas, Ramon
    Grande, Enrique
    Garcia-Donas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study.
    Garcia-Donas, Jesus
    Garrigos, Laia
    Lainez, Nuria
    Santaballa, Ana
    Redondo, Andres
    Cueva, Juan Fernando
    Rubio, M. Jesus
    Prieto, Mario
    Lopez-Guerrero, Jose Antonio
    Garcia-Casado, Zaida
    Grande, Enrique
    Alia, Eva Guerra
    Bover, Isabel
    Polo, Susana Hernando
    Sanchez-escribano, Ricardo
    Hurtado, Alicia
    Navarro, Paloma
    Rodriguez-Moreno, Juan Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)
    Garcia-Donas, Jesus
    Garrigos, Laia
    Lainez, Nuria
    Santaballa, Ana
    Redondo, Andres
    Cueva, Juan Fernando
    Rubio, M. Jesus
    Prieto, Mario
    Lopez-Guerrero, Jose Antonio
    Garcia-Casado, Zaida
    Barquin, Aranzanzu
    Grande, Enrique
    Alia, Eva Guerra
    Sevillano, Elena
    Bover, Isabel
    Grazioso, Tatiana P.
    Sanchez-Escribano, Ramon
    Hurtado, Alicia
    Navarro, Paloma
    Rodriguez-Moreno, Juan Francisco
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [4] Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study-GETHI 2013-01.
    Rodriguez-Moreno, Jf.
    Garcia-Donas, Jesus
    Garrigos, Laia
    Lainez, Nuria
    Santaballa, Ana
    Redondo, Andres
    Fernando Cueva, Juan
    Jesus Rubio, Maria
    Hernando Polo, Susana
    Bover, Isabel
    Palacio, Isabel
    Garcia-Casado, Zaida
    Grande, Enrique
    Hurtado, Alicia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03
    Jesus Garcia-Donas
    Alicia Hurtado
    Laia Garrigos
    Ana Santaballa
    Andres Redondo
    Laura Vidal
    Nuria Lainez
    Eva Guerra
    Victor Rodriguez
    Juan Cueva
    Isabel Bover
    Isabel Palacio
    Maria Jesus Rubio
    Mario Prieto
    Jose Antonio Lopez-Guerrero
    Juan Francisco Rodriguez-Moreno
    Zaida Garcia-Casado
    Elena Garcia-Martinez
    Alvaro Taus
    Ignacio Pérez de Castro
    Paloma Navarro
    Enrique Grande
    Clinical and Translational Oncology, 2023, 25 : 2090 - 2098
  • [6] Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03
    Garcia-Donas, Jesus
    Hurtado, Alicia
    Garrigos, Laia
    Santaballa, Ana
    Redondo, Andres
    Vidal, Laura
    Lainez, Nuria
    Guerra, Eva
    Rodriguez, Victor
    Cueva, Juan
    Bover, Isabel
    Palacio, Isabel
    Rubio, Maria Jesus
    Prieto, Mario
    Lopez-Guerrero, Jose Antonio
    Rodriguez-Moreno, Juan Francisco
    Garcia-Casado, Zaida
    Garcia-Martinez, Elena
    Taus, Alvaro
    de Castro, Ignacio Perez
    Navarro, Paloma
    Grande, Enrique
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (07): : 2090 - 2098
  • [7] Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study
    Dreicer, R.
    Agus, D. B.
    MacVicar, G. R.
    Wang, J.
    MacLean, D.
    Stadler, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase I, Open-Label, Single-Dose Study
    Suri, Ajit
    Pusalkar, Sandeepraj
    Li, Yuexian
    Prakash, Shimoga
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (03): : 180 - 187
  • [9] Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
    Agus, David B.
    Stadler, Walter Michael
    Shevrin, Daniel H.
    Hart, Lowell
    MacVicar, Gary R.
    Hamid, Omid
    Hainsworth, John D.
    Gross, Mitchell E.
    Wang, Jingyuan
    Webb, Iain James
    MacLean, David
    Dreicer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [10] Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01)
    Garcia-Donas, Jesus
    Redondo, Andres
    Santaballa, Ana
    Garrigos, Laia
    Rubio, M. Jesus
    Lainez, Nuria
    Gonzalez, Maria Iglesias
    Cueva, Juan Fernando
    Barquin, Arantzazu
    Grazioso, Tatiana P.
    Hurtado, Alicia
    Sevillano, Elena
    Grande, Enrique
    Rodriguez-Moreno, Juan Francisco
    Navarro, Paloma
    GYNECOLOGIC ONCOLOGY, 2024, 191 : 233 - 239
12345